The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shirasugi, N.
Right arrow Articles by Larsen, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shirasugi, N.
Right arrow Articles by Larsen, C. P.
The Journal of Immunology, 2002, 169: 2677-2684.
Copyright © 2002 by The American Association of Immunologists

Prevention of Chronic Rejection in Murine Cardiac Allografts: A Comparison of Chimerism- and Nonchimerism-Inducing Costimulation Blockade-Based Tolerance Induction Regimens1

Nozomu Shirasugi, Andrew B. Adams, Megan M. Durham, Aron E. Lukacher, Huaying Xu, Phyllis Rees, Shannon R. Cowan, Matthew A. Williams, Thomas C. Pearson2 and Christian P. Larsen2

The Carlos and Marguerite Mason Transplantation Biology Research Center, Departments of Surgery, Emory University School of Medicine, Atlanta, GA 30322

We have previously described a nonirradiation-based regimen combining costimulation blockade, busulfan, and donor bone marrow cells that promotes stable, high level chimerism, deletion of donor-reactive T cells, and indefinite survival of skin allografts in mice. The purpose of the current study is to determine the efficacy of this tolerance regimen in preventing acute and chronic rejection in a vascularized heart graft model and to compare this regimen with other putative tolerance protocols. Mice receiving costimulation blockade (CTLA4-Ig and anti-CD40 ligand) alone or in combination with donor cells enjoyed markedly prolonged heart graft survival and initially preserved histological structure. However, tolerance was not achieved, as evidenced by the eventual onset of chronic rejection characterized by obliterative vasculopathy and the rejection of secondary skin grafts. In contrast, following treatment with costimulation blockade, busulfan, and bone marrow, heart grafts survived indefinitely without detectable signs of chronic rejection or structural damage, even 100 days after placement of a secondary donor skin graft. We detected multilineage chimerism in peripheral blood, spleen, lymph nodes, and thymus, and peripheral deletion of donor-reactive cells was complete by day 90. These findings indicate that only the CD40/CD28 blockade chimerism induction regimen prevents both acute and chronic rejection of vascularized organ transplants. Further testing of these strategies in a preclinical large animal model is warranted.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. M. Gorczynski, Z. Chen, W. He, I. Khatri, Y. Sun, K. Yu, and I. Boudakov
Expression of a CD200 Transgene Is Necessary for Induction but Not Maintenance of Tolerance to Cardiac and Skin Allografts
J. Immunol., August 1, 2009; 183(3): 1560 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Tchorsh-Yutsis, G. Hecht, A. Aronovich, E. Shezen, Y. Klionsky, C. Rosen, R. Bitcover, S. Eventov-Friedman, H. Katchman, S. Cohen, et al.
Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes: Transient Treatment With Anti-LFA1, Anti-CD48, and FTY720 Enables Long-Term Graft Maintenance in Mice With Only Mild Ongoing Immunosuppression
Diabetes, July 1, 2009; 58(7): 1585 - 1594.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Hu, D. Watson, G. Y. Zhang, N. Graf, Y. M. Wang, M. Sartor, B. Howden, J. Fletcher, and S. I. Alexander
Long-Term Cardiac Allograft Survival across an MHC Mismatch after "Pruning" of Alloreactive CD4 T Cells
J. Immunol., May 15, 2008; 180(10): 6593 - 6603.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. H. Cook, A. A. Bickerstaff, J.-J. Wang, T. Nadasdy, P. Della Pelle, R. B. Colvin, and C. G. Orosz
Spontaneous Renal Allograft Acceptance Associated with "Regulatory" Dendritic Cells and IDO
J. Immunol., March 1, 2008; 180(5): 3103 - 3112.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Guillonneau, C. Seveno, A.-S. Dugast, X.-L. Li, K. Renaudin, F. Haspot, C. Usal, J. Veziers, I. Anegon, and B. Vanhove
Anti-CD28 Antibodies Modify Regulatory Mechanisms and Reinforce Tolerance in CD40Ig-Treated Heart Allograft Recipients
J. Immunol., December 15, 2007; 179(12): 8164 - 8171.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
W Chalermskulrat, K P McKinnon, W J Brickey, I P Neuringer, R C Park, D G Sterka, B R Long, P McNeillie, R J Noelle, J P Ting, et al.
Combined donor specific transfusion and anti-CD154 therapy achieves airway allograft tolerance
Thorax, January 1, 2006; 61(1): 61 - 67.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Bushell, E. Jones, A. Gallimore, and K. Wood
The Generation of CD25+CD4+ Regulatory T Cells That Prevent Allograft Rejection Does Not Compromise Immunity to a Viral Pathogen
J. Immunol., March 15, 2005; 174(6): 3290 - 3297.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Metzler, P. Gfeller, M. Bigaud, J. Li, G. Wieczorek, C. Heusser, P. Lake, and A. Katopodis
Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection
J. Immunol., December 1, 2004; 173(11): 7025 - 7036.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.